Skip to content
Clinical Trials – home

Ichthyosis Treatment

1 / 2 trials open to patients1 country

In short

Ichthyosis is a group of rare genetic skin conditions that result in extremely dry, thick, and scaly skin resembling fish scales. While there is currently no cure for most types of ichthyosis, modern medicine offers several ways to manage symptoms and improve patients' quality of life through both established therapies and experimental approaches being tested in clinical research.

Key points

  • Ichthyosis requires lifelong management rather than a cure, with treatment focusing on controlling symptoms and improving quality of life.
  • Regular moisturizing with emollients forms the foundation of treatment for all types of ichthyosis, ideally applied when skin is still damp after bathing.
  • Keratolytic agents like salicylic acid and lactic acid help remove thick scales but may need adjustment if irritation occurs.
  • Retinoid medications offer powerful treatment for severe cases but require specialist supervision due to potential side effects and pregnancy risks.
  • Clinical trials are exploring innovative approaches including drug repositioning, immunomodulating agents, and therapies targeting specific genetic mutations.
  • Treatment plans must be individualized based on the specific type of ichthyosis, symptom severity, and how each patient's skin responds to different therapies.
  • Some forms of acquired ichthyosis may improve if the underlying medical condition is treated or the triggering medication is changed.
  • Patients using paraffin-containing emollients must avoid open flames due to fire risk, and should use emollient soap substitutes rather than regular soap.

Understanding the Treatment Landscape for Ichthyosis

Living with ichthyosis presents unique challenges that go far beyond simple dry skin. The condition affects how skin cells develop, shed, and protect the body, leading to a buildup of thick, scaly patches that can cover large areas of the body. The primary goal of treatment is not to cure the condition, but rather to manage its symptoms effectively so that people with ichthyosis can live comfortably and confidently.

Treatment approaches vary significantly depending on the specific type of ichthyosis a person has, the severity of their symptoms, and their age. Some individuals may have mild symptoms that respond well to simple moisturizing routines, while others require more intensive medical interventions. The thickness and color of scales, the areas of the body affected, and whether complications like infections or overheating occur all influence which treatments doctors recommend.

Medical teams typically approach ichthyosis treatment in layers, starting with the most basic and safest options before moving to more complex therapies. This strategy ensures that patients receive the least invasive treatment that effectively controls their symptoms. At the same time, researchers continue exploring new therapeutic approaches through clinical trials, searching for more effective ways to address the underlying causes of various ichthyosis types.

Because ichthyosis is a lifelong condition for most people, treatment is not about achieving a complete cure but about finding sustainable ways to keep the skin as healthy and comfortable as possible. This requires ongoing care, regular adjustments to treatment plans, and often a combination of different approaches working together.

Standard Treatment Options for Managing Ichthyosis

The foundation of ichthyosis treatment rests on meticulous skin care, particularly the regular use of emollients, which are moisturizing treatments that help keep the skin hydrated. Emollients work by creating a barrier on the skin's surface that prevents water from evaporating, while also adding moisture back into the dry, scaly patches. These products come in various forms including lotions, creams, ointments, and bath oils, and patients often need to experiment to find which formulations work best for their particular skin type.

The timing of emollient application matters significantly. Dermatologists recommend applying these moisturizing products at least once daily, ideally immediately after bathing or showering while the skin is still damp. This technique helps trap moisture in the skin rather than allowing it to evaporate. Some people with ichthyosis may need to apply emollients multiple times throughout the day to maintain adequate hydration. Common examples of moisturizing ingredients include petroleum jelly, mineral oil, ceramides, and urea.

Beyond simple moisturizing, many patients benefit from keratolytic agents, which are substances that help loosen and remove the thick scales that accumulate on the skin. These peeling creams work by breaking down the proteins that hold dead skin cells together, making it easier for the scales to shed naturally. Salicylic acid is one commonly used keratolytic agent, typically applied in cream form at concentrations ranging from one to five percent. Lactic acid is another option that not only helps remove scales but also provides moisturizing benefits.

Other keratolytic options include ammonium lactate creams, hydroxy acid formulations, and urea creams at various strengths. However, these agents can sometimes cause irritation, leading to redness, stinging, itching, or discomfort. When this occurs, doctors can adjust the strength of the cream or recommend switching to a different formulation. It's important to find a balance between effectively removing scales and maintaining skin comfort.

For more severe cases of ichthyosis that don't respond adequately to moisturizers and keratolytics alone, doctors may prescribe retinoids, which are medications derived from vitamin A. Retinoids work by affecting how skin cells grow and shed, helping to normalize the skin renewal process. These medications can be applied topically as creams or taken orally as tablets, depending on the severity of the condition.

Oral retinoids such as isotretinoin and acitretin have shown impressive results in reducing scaling, discomfort, and the cosmetic impact of ichthyosis. These medications affect the entire body's skin renewal process, making them particularly effective for widespread or severe symptoms. However, retinoids require careful monitoring because they can cause significant side effects. Common problems include dryness of the eyes, lips, and nose, as well as nosebleeds, headaches, nausea, and elevated blood cholesterol levels.

A critical concern with retinoid therapy is that these medications can cause serious birth defects if taken during pregnancy. For this reason, retinoids can only be prescribed by dermatologists who specialize in their use, and patients taking them require regular check-ups and blood tests to monitor for complications. Once retinoid treatment is stopped, the ichthyotic skin typically returns, which means patients may need long-term therapy to maintain improvements.

When ichthyosis leads to bacterial skin infections, which can occur when the protective skin barrier is compromised, doctors prescribe antibiotics either topically or orally to treat or prevent these complications. Some patients with severe types of ichthyosis, particularly those with blistering forms like epidermolytic hyperkeratosis, may require long-term antibiotic therapy to manage chronic infections that produce an unpleasant skin odor.

The duration of standard treatment for ichthyosis is typically lifelong, as most genetic forms of the condition persist throughout a person's life. However, some types of acquired ichthyosis that develop due to another health condition or medication may improve if the underlying cause can be addressed. For example, treating kidney disease or changing a medication that triggered ichthyosis symptoms can lead to skin improvement.

Emerging Therapies in Clinical Research

While standard treatments help manage ichthyosis symptoms, researchers continue searching for more targeted approaches that address the underlying genetic and molecular causes of different ichthyosis types. Clinical trials represent an important avenue for testing these innovative therapies before they become widely available to patients.

One promising area of research involves understanding how specific genetic mutations lead to ichthyosis symptoms. For example, scientists have identified that many cases of ichthyosis vulgaris result from mutations in the gene that produces filaggrin, a protein essential for forming the skin's protective barrier. This knowledge has led researchers to explore therapies that might compensate for the lack of functional filaggrin or enhance the skin barrier through alternative mechanisms.

Another compound being investigated for severe ichthyosis is liarozole, an imidazole derivative that works by inhibiting the breakdown of retinoic acid in the body. By preventing the enzyme that normally clears retinoic acid, liarozole increases the levels of this vitamin A derivative in tissues, which leads to reduced skin cell proliferation and decreased scaling. Clinical studies have explored liarozole at doses of 150 milligrams twice daily, though it has not yet received widespread approval for ichthyosis treatment.

For patients with Sjögren-Larsson syndrome, a rare form of syndromic ichthyosis caused by a deficiency in an enzyme called fatty aldehyde dehydrogenase, researchers are investigating whether existing medications might help. Bezafibrate, a drug normally used to lower cholesterol and other blood fats, has shown promise in early research. The medication appears to induce increased activity of the deficient enzyme in patients who still have some residual enzyme function, potentially improving their skin symptoms.

Topical immunomodulating agents represent another area of clinical investigation. Pimecrolimus, a cream containing one percent of an immunomodulating agent, has been tested in patients with Netherton syndrome, a rare and severe form of ichthyosis. This medication, which is already approved for treating atopic dermatitis, works by dampening certain immune responses in the skin. Its effects are similar to another immunomodulator called tacrolimus, but pimecrolimus may have fewer side effects related to fat metabolism.

Calcipotriene, a vitamin D derivative ointment, has also been studied for its potential benefits in hyperproliferative variants of ichthyosis where skin cells are produced too rapidly. This medication helps regulate skin cell growth and differentiation. However, its use in treating congenital hyperproliferative disorders remains limited because of theoretical concerns about hypercalcemia, a condition where too much calcium accumulates in the blood from absorption of the drug through large areas of affected skin.

The field of drug repositioning offers particular promise for ichthyosis treatment. Repositioning involves taking medications that are already approved and well-understood for one condition and testing them for effectiveness against another condition. This approach can potentially lead to faster availability of new treatments compared to developing entirely new drugs from scratch, while also potentially reducing costs. Researchers are systematically evaluating existing medications and biologics to identify candidates that might benefit people with various forms of ichthyosis.

Most clinical trials for ichthyosis treatments progress through several phases. Phase I trials primarily test safety and determine appropriate dosing in small groups of participants. Phase II trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety in larger groups. Phase III trials compare the experimental treatment directly against standard care in even larger patient populations to definitively determine if the new approach offers advantages. The specific phase and location of trials vary depending on the therapy being tested and the research team conducting the study.

Most common treatment methods

  • Moisturizing therapy (emollients)
    • Lotions, creams, ointments, and bath oils applied regularly to hydrate skin and prevent water loss
    • Products containing petroleum jelly, mineral oil, ceramides, or urea
    • Applied at least once daily, ideally on damp skin after bathing
    • Forms the foundation of treatment for all types of ichthyosis
  • Keratolytic agents
    • Peeling creams that help remove thick scales by loosening dead skin cells
    • Salicylic acid at concentrations of one to five percent
    • Lactic acid creams that also provide moisturizing benefits
    • Ammonium lactate, hydroxy acid creams, and urea creams at various strengths
    • May cause irritation, requiring adjustment of concentration or formulation
  • Retinoid therapy
    • Vitamin A derivatives available as topical creams or oral tablets
    • Oral medications include isotretinoin and acitretin
    • Tretinoin cream for topical application
    • Help normalize skin cell growth and shedding processes
    • Require careful monitoring for side effects including dry eyes, lips, and nose, nosebleeds, headaches, and elevated cholesterol
    • Cannot be used during pregnancy due to risk of birth defects
    • Only prescribed by dermatologists with regular check-ups and blood tests
  • Antibiotic treatment
    • Used to treat or prevent bacterial skin infections
    • May be applied topically or taken orally
    • Long-term therapy sometimes needed for chronic infections in severe cases
  • Experimental therapies in clinical trials
    • Liarozole to increase retinoic acid levels in tissues
    • Bezafibrate for Sjögren-Larsson syndrome to increase enzyme activity
    • Pimecrolimus cream for immunomodulation in Netherton syndrome
    • Calcipotriene ointment for hyperproliferative variants
    • Drug repositioning studies exploring existing medications for new uses

Did you know?

  1. The name "ichthyosis" comes from the ancient Greek word "ichthys" meaning fish, because the thick, plate-like scales on some patients' skin resemble fish scales.
  2. Some people with X-linked ichthyosis can develop painless spots on the surface of their eyes called asymptomatic specks, though these don't interfere with vision.
  3. Mothers carrying male babies with X-linked ichthyosis may experience prolonged and difficult labor due to the genetic deficiency affecting hormone production.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Ichthyosis

Recruiting trials first

See all 2 trials →
Quick filters

2 clinical trials in this condition

Ichthyosis

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gentamicin Sulfate
  • Sponsor:Centre Hospitalier Universitaire De Toulouse
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Centre Hospitalier Universitaire De Nice
See all 2 trials →filters applied: condition = Ichthyosis

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).